BASF Articles
BASF sells pharma business to Abbott Labs for $6.9 billion in cash
15 December 2000
Stock Commentary - Europe
14 December 2000
Stock Commentary - Europe
7 December 2000
BASF wins positive opinion for Reductil in EU
22 November 2000
BASF to close Notts, UK, R&D site
20 November 2000
Bayer views possible acquisition
20 November 2000
Stock Commentary - New York
16 November 2000
Stock Commentary - Europe
16 November 2000
BASF excited about prospects for D2E7, as rumor mill talks of pharma
15 November 2000
Appointment at BASF UK
19 October 2000
Stock Commentary Europe
12 October 2000
BASF looking to launch new pain drug in 2001
3 October 2000
Stock Commentary Europe
28 September 2000
Dow signs discovery deal with Symyx
25 September 2000
Stock Commentary Europe
21 September 2000
BASF Pharma licenses oncology candidates to ILEX
7 September 2000
Stock Commentary Tokyo
7 September 2000
Stock Commentary Europe
17 August 2000
Stock Commentary Tokyo
3 August 2000
Stock Commentary Europe
3 August 2000
Cambridge Antibody: R&D update
2 August 2000
BASF and Takeda to combine vitamin ops
31 July 2000
Stock Commentary Tokyo
20 July 2000
Stock Commentary Tokyo
13 July 2000
EC clears BASF purchase of American Cyanamid
6 July 2000
Stock Commentary Europe
29 June 2000
Stock Commentary Europe
22 June 2000
Appointment at BASF
8 June 2000
Knoll sells urology unit to Abbott Labs
6 June 2000
CAT to list in USA
25 May 2000
Foreign shareholders own 37.8% of BASF
3 May 2000
"Fantastic" start to 2000 for BASF
28 April 2000
BASF Pharma to focus on R&D; to sell UK site
20 April 2000
AHP posts 18% net income growth
20 April 2000
Stock Commentary Europe
19 April 2000
Stock Commentary Europe
13 April 2000
BASF's ancrod fails in Ph III stroke trial
31 March 2000
Bayer's US health care sales jump 21% in 1999
31 March 2000
Stock Commentary Europe
23 March 2000
Bayer structure to remain intact UPDATE
20 March 2000
Stock Commentary Europe
16 March 2000
Stock Commentary Europe
9 March 2000
Boots and BASF accused in Canada
29 February 2000
French generics market takes off at last
28 February 2000
Stock Commentary Europe
24 February 2000
Stock Commentary Tokyo
17 February 2000
Stock Commentary Europe
17 February 2000
BASF Pharma sets 15%-20% return on sales target
14 February 2000
BASF moves into Phase III with D2E7
7 February 2000
Appointment at BASF
3 February 2000
Stock Commentary Tokyo
3 February 2000
Smith & Nephew buys BASF's wound-care product, takes market lead
3 February 2000
Stock Commentary Europe
27 January 2000
Stock Commentary Tokyo
27 January 2000
Stock Commentary Europe
20 January 2000
Monsanto pays out $81 million break-up fee
5 January 2000
Knoll AG in deal with Evotec BioSystems
22 December 1999
Stock Commentary Europe
16 December 1999
Stock Commentary Europe
2 December 1999
DevCo Pharmaceuticals completes Ph II with Parkinson's drug
29 November 1999
BASF loses IP challenge against Peptech
29 November 1999
Stock Commentary Europe
25 November 1999
Stock Commentary Europe
18 November 1999
BASF profits hit badly by vitamins charge, Meridia sales stagnate
17 November 1999
Stock Commentary Europe
4 November 1999
New chairman for BASF AG
28 October 1999
Stock Commentary Europe
28 October 1999
BASF chairman dies
21 October 1999
Stock Commentary Europe
30 September 1999
BASF a market outperformer, say GS analysts
24 September 1999
Stock Commentary Europe
23 September 1999
BASF Pharma hoping to catch up with top pharmaceutical companies
23 September 1999
BASF Pharma first-half sales up 9% and speeding up
21 September 1999
Japanese reaction to US vitamin lawsuits
15 September 1999
Vitamin price-fixing settlements close?
9 September 1999
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
